C. Smith

J. Kurtzberg, C. Smith, S. Castellino, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys.

E. Gilboa, S. W. Lee, J. Lebkowski, 1996, Antiviral research.

An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies

B. Sullenger, C. Smith, R. Howrey, 2000, Gene Therapy.

Immunotherapy for Epstein-Barr virus-associated cancers.

H. Heslop, C. Rooney, C. Smith, 1998, Journal of the National Cancer Institute. Monographs.

Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells.

E. Gilboa, C. Bordignon, C. Smith, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication

T. Lee, B. Sullenger, E. Gilboa, 1990, Molecular and cellular biology.

Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype.

E. Gilboa, Y. Kanakura, R. Ware, 2001, Blood.

AIDS and HIV infection.

B. Sullenger, C. Smith, Bruce A. Sullenger, 1995, Molecular and cell biology of human diseases series.

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

D. Srivastava, R. Krance, H. Heslop, 1998, Blood.

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.

H. Heslop, C. Rooney, C. Smith, 1995, Journal of hematotherapy.

Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain

E. Gilboa, S. W. Lee, C. Smith, 1994, Journal of virology.

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

R. Krance, H. Heslop, C. Rooney, 1995, The Lancet.

High-efficiency retroviral vector mediated gene transfer into human peripheral blood CD4+ T lymphocytes.

E. Gilboa, T. Rudoll, C. Smith, 1996, Gene therapy.

Multiparameter-fluorescence activated cell sorting analysis of retroviral vector gene transfer into primitive umbilical cord blood cells.

E. Gilboa, J. Kurtzberg, C. Smith, 1998, Experimental hematology.

Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA.

B. Sullenger, C. Smith, S. W. Lee, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Extensive cross-reactivity of adenovirus-specific cytotoxic T cells.

C. Rooney, C. Smith, G. Kitchingman, 1998, Human gene therapy.

Retroviral vector-mediated gene transfer into umbilical cord blood CD34brCD38-CD33- cells.

C. Smith, T. Gentry, 1999, Experimental hematology.

Inhibition of HIV-1 in CEM cells by a potent TAR decoy.

E. Gilboa, S. W. Lee, C. Smith, 1995, Gene therapy.

Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors.

B. Sullenger, C. Smith, S. W. Lee, 1998, Science.

Transfer of marker genes into hemopoietic progenitor cells.

R. Krance, H. Heslop, C. Rooney, 1996, Cytokines and molecular therapy.

Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.

R. Krance, H. Heslop, C. Rooney, 1994, Human gene therapy.